Hp Diagnostic Test

[Analisa Wack]

Thesite is secure.

The ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

These at-home OTC COVID-19 diagnostic tests are FDA authorized for self-testing at home (or in other locations) without a prescription. Tests are available online or at local stores and you collect your own sample, perform the test, and read the result yourself without the need to send a sample to a laboratory.

With most at-home OTC COVID-19 diagnostic tests, you should repeat testing following a negative result, whether you have symptoms or not, to reduce your risk of a false negative test result. The FDA encourages you to voluntarily and anonymously report your positive or negative test results every time you use an at-home COVID-19 test. You can send your test result to MakeMyTestCount.org or use an app or other digital option for self-reporting that may be included with your test. For additional information on reading and understanding your test results, see Understanding At-Home OTC COVID-19 Antigen Diagnostic Test Results.

The table below is updated regularly and lists FDA-authorized at-home OTC COVID-19 diagnostic tests, including information on expiration dates, who can use the test, links to home use instructions for each test, and other details that may help you decide what test is right for you. For additional information about each Emergency Use Authorization (EUA), see In Vitro Diagnostics EUAs: Tables of IVD EUAs.

In the table below, the "Expiration Date" column lists where to find the expiration date for that test, and the "Other Details" column lists the shelf-life for the test. The shelf-life is how long the test should work as expected and is measured from the date the test was manufactured. The expiration date is set at the end of the shelf-life and is the date through which the test is expected to perform as accurately as when manufactured. In some cases, the expiration date for a test may be extended.

An extended expiration date means the manufacturer provided data showing that the shelf-life is longer than was known when the test was first authorized. For more information about how the expiration date is determined and why it may be extended, see the At-Home COVID-19 Diagnostic Tests: Frequently Asked Questions.

For symptomatic persons with dengue virus infection, dengue virus RNA can usually be detected by molecular tests for the first 0-7 days in the course of illness. After day 7, molecular tests may not be as sensitive.

NS1 is detectable during the acute phase of dengue virus infections. NS1 tests can be as sensitive as molecular tests during the first 0-7 days of symptoms. After day 7, NS1 tests may not be as sensitive.

IgM antibody testing can identify most recent dengue infections after day 3 of illness. These tests should be run on samples with negative NS1 and PCR results, particularly after day 3 of illness. Interpreting positive IgM results is complicated because of cross-reactivity with other flaviviruses, like Zika.

Plaque Reduction Neutralization Tests (PRNT) can resolve false-positive IgM antibody results caused by non-specific reactivity, and, in some cases, can help identify the infecting virus. However, in areas with high prevalence of dengue and Zika virus neutralizing antibodies, PRNT may not confirm a significant proportion of IgM positive results.

Cross reactivity is a limitation of dengue serological tests and is seen when antibodies against other flaviviruses react on the dengue IgM test. For people living in or traveling to an area with concurrently circulating flaviviruses, clinicians will need to order plaque reduction neutralization test (PRNT) to rule out dengue on IgM-positive specimens. Physicians may consult with state or local public health laboratories or CDC for guidance. Zika, Japanese encephalitis, St. Louis encephalitis, West Nile, and yellow fever viruses are examples of other flaviviruses to be considered when ruling out dengue by PRNT. PRNT does not always a give conclusive diagnostic result, particularly in patients that have previously been exposed to more than one flavivirus. Current dengue molecular tests (E.g., RT-PCR) and NS1 tests do not have cross-reactivity with other flaviviruses of concern.

RIDTs may be used to help with diagnostic and treatment decisions for patients in clinical settings, such as whether to prescribe antiviral medications. However, due to the limited sensitivities, negative results of RIDTs do not exclude influenza virus infection in patients with signs and symptoms suggestive of influenza. Therefore, if clinically indicated, antiviral treatment should not be withheld from patients with suspected influenza, even if they test negative by RIDT, and further influenza testing of respiratory specimens by molecular assays may be indicated. More information about Antiviral Drugs and recommendations on their use.

Testing is not needed for all patients with signs and symptoms of influenza to make antiviral treatment decisions (See Figures 1-4). Once influenza activity has been documented in the community or geographic area, a clinical diagnosis of influenza can be made for outpatients with signs and symptoms consistent with suspected influenza, especially during periods of peak influenza activity in the community.

RIDTs can be useful to identify influenza virus infection as a cause of respiratory outbreaks in any setting, but especially in institutions (i.e., nursing homes, chronic care facilities, and hospitals), cruise ships, summer camps, schools, etc. Positive RIDT results from one or more ill persons with suspected influenza can support decisions to promptly implement infection prevention and control measures for influenza outbreaks. However, negative RIDT results do not exclude influenza virus infection as a cause of a respiratory outbreak because of the limited sensitivity of these tests. Testing respiratory specimens from several persons with suspected influenza will increase the likelihood of detecting influenza virus infection if influenza virus is the cause of the outbreak, and use of molecular assays such as RT-PCR is recommended if the cause of the outbreak is not determined and influenza is suspected. Public health authorities should be notified promptly of any suspected institutional outbreak and respiratory specimens should be collected from ill persons (whether positive or negative by RIDT) and sent to a public health laboratory for more accurate influenza testing by molecular assays and viral culture.

Proper interpretation of RIDT results is very important for clinical management of patients and for assessing suspected influenza outbreaks. A number of factors can influence the results of RIDTs. The accuracy of RIDTs depends largely on the conditions under which they are used. Understanding some basic considerations can minimize being misled by false-positive or false-negative results.

Clinicians should contact their local or state health department for information about current influenza activity. For more information about influenza activity in the United States during the influenza season, visit the Weekly U.S. Influenza Surveillance Report (FluView).

Influenza testing is recommended for hospitalized patients with suspected influenza. Molecular assays such as RT-PCR are recommended for testing hospitalized patients. However, empiric antiviral treatment should be initiated as soon as possible for hospitalized patients with suspected influenza without the need to wait for any influenza testing results (see Antiviral Drugs, Information for Health Care Professionals). Antiviral treatment should not be stopped based on negative RIDT results given the limited sensitivities of RIDTs. Infection prevention and control measures should be implemented immediately upon admission for any hospitalized patient with suspected influenza even if RIDT results are negative (see Prevention Strategies for Seasonal Influenza in Heath Care Settings). Serology for influenza should not be performed for clinical management. Clinicians should understand that negative results of influenza testing do not exclude influenza virus infection, especially if the time from illness onset to collection of respiratory specimens is more than 3 days, or if upper respiratory tract specimens were tested and the patient has lower respiratory tract disease. If influenza is suspected, testing of clinical specimens collected from different respiratory sites can be done (e.g., upper and lower respiratory tract) and can be collected on more than one day to increase the likelihood of influenza virus detection; intubated patients should have endotracheal aspirate specimens tested if influenza is suspected, but not yet confirmed.

Detection of influenza virus infection and prompt implementation of infection prevention and control measures is critical to prevention of nosocomial influenza outbreaks. When there is influenza activity in the community, clinicians should consider influenza testing, including viral culture, for patients who develop signs and symptoms of influenza while they are in a health care facility. This should be done as part of a broader surveillance strategy for influenza as discussed in Prevention Strategies for Seasonal Influenza in Heath Care Settings.

For suspected influenza outbreaks in institutions, respiratory specimens should be collected from patients with suspected influenza as early as possible once the outbreak is suspected (See Figure 2). The use of influenza molecular assays is preferred. If RIDTs are used in these settings, clinical specimens should also be sent for influenza testing by viral culture and RT-PCR to provide detailed information on specific influenza A virus subtypes and strains, and antiviral susceptibility data and to verify RIDT test results. Active daily surveillance for suspected influenza illness and collection of specimens from patients with suspected influenza should continue through at least 2 weeks after implementation of control measures to assess effectiveness of the measures and to monitor for potential emergence of antiviral resistance. See Prevention Strategies for Seasonal Influenza in Heath Care Settings.

3a8082e126